title: [Pancreatic infringement exocrine and endocrine in cystic fibrosis].
abstract: The exocrine pancreatic insufficiency affects more than 80% of cystic fibrosis (CF) infants. Pancreatic insufficiency is diagnosed by low levels of fecal elastase. An optimal caloric intake, a pancreatic enzyme treatment are the keys to maintain a good nutritional status. The fat soluble vitamins supplementation will be associated with pancreatic enzymes treatment and will be adapted to plasma levels. Iron and oligo-element deficiency such as zinc is common. The pancreatic enzymes function is not optimal in the proximal bowel: the intraluminal intestinal pH is low because of the absence of bicarbonate release by the pancreas. The use of proton pump inhibitors may improve the functionality of pancreatic enzymes treatment. New therapies such as ivacaftor in patients with a G551D mutation allows a weight gain in particular by restoring intestinal pH similar to controls. Lengthening of the life expectancy of patients with CF is accompanied by the emergence new aspects of the disease, especially diabetes, favored by pancreatic cystic fibrosis resulting in an anatomical destruction of pancreatic islets. Currently, diabetes affects a third of the patients after 20 years, and half after 30 years. Cystic fibrosis-related diabetes is a major factor of morbidity-mortality in all stages of the disease and is characterized by a preclinical phase of glucose intolerance particularly long reaching up to 10 years. Its pathophysiology combines a lack of insulin secretion, an insulin resistance secondary to chronic infection, and a decrease in the production of the GIP and GLP-1. The insulin secretion depending on the channel chlorine (Cystic Fibrosis Transmembrane conductance Regulator [CFTR]) activity at the membrane surface of insulin cell is reduced prior to the occurrence of pancreatic histological lesions. At the stage of diabetes, obtaining a normoglycemia by insulin treatment began very early allows to slow the decline of lung function and nutritional status. Given the silent phase of diabetes, screening it is recommended by the realization of an annual OGTT from 10 years of age, or before in severe forms of CF. New treatments of CF able to target CFTR showed their efficacy in slowing the decline of lung function, and could also contribute to slow or prevent the onset of diabetes.
authors.affiliation: Service d'endocrinologie-diabète-nutrition, Hôpital Civil, Hôpitaux Universitaires de Strasbourg; Centre de ressources et de compétences de la mucoviscidose d'Alsace; Équipe d'accueil 7293 Stress vasculaire et tissulaire en transplantation; Université de Strasbourg, France. Electronic address: laurence.kessler@chru-strasbourg.fr.
authors.forename: L
authors.initials: L
authors.lastname: Kessler
authors.affiliation: Centre de ressources et de compétences de la mucoviscidose Reims, American Memorial Hospital CHU Reims; INSERM UMRS 903 Reims, France.
authors.forename: M
authors.initials: M
authors.lastname: Abély
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000175:diagnosis* / Q000503:physiopathology* / Q000628:therapy; D003920:Diabetes Mellitus / Q000175:diagnosis* / Q000503:physiopathology* / Q000628:therapy; D002149:Energy Intake / Q000502:physiology; D010188:Exocrine Pancreatic Insufficiency / Q000175:diagnosis* / Q000503:physiopathology* / Q000628:therapy; D005951:Glucose Tolerance Test; D006801:Humans; D007223:Infant; D007515:Islets of Langerhans / Q000503:physiopathology*; D008017:Life Expectancy; D046790:Pancreas, Exocrine / Q000503:physiopathology*; D010184:Pancreatic Extracts / Q000627:therapeutic use; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D010184:Pancreatic Extracts; D054328:Proton Pump Inhibitors